What it's for (Indications)
- Alglucosidase alfa is specifically indicated as a long-term enzyme replacement therapy (ERT) for patients diagnosed with Pompe disease, also known as glycogen storage disease type II or acid alpha-glucosidase (GAA) deficiency.
- This inherited metabolic disorder results in the accumulation of glycogen within lysosomes in various tissues, primarily muscle, leading to progressive muscle weakness, respiratory insufficiency, and cardiomyopathy.
- The therapy is approved for both infantile-onset Pompe disease, characterized by rapid progression and severe cardiomyopathy, and late-onset Pompe disease, which typically presents with a more variable age of onset and progression, primarily affecting skeletal and respiratory muscles.
- This targeted treatment aims to supply the deficient lysosomal enzyme, thereby facilitating the breakdown of accumulated glycogen and mitigating disease progression, ultimately improving motor function and reducing organomegaly.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended dosage of alglucosidase alfa is 20 mg/kg of body weight, administered intravenously once every two weeks. The initial infusion rate should be slow, typically beginning at 1 mg/kg/hour, and gradually increased by 2 mg/kg/hour every 30 minutes, if tolerated, up to a maximum rate of 7 mg/kg/hour. Close monitoring of the patient throughout the infusion is paramount, particularly during the initial phase and during dose escalations, to promptly identify and manage any infusion-related reactions. Pre-treatment with antihistamines, antipyretics, and/or corticosteroids may be considered for patients who experience mild to moderate infusion-related reactions or as a prophylactic measure to mitigate their occurrence. Dilution of the reconstituted drug is required, and it must be administered using an in-line, low protein-binding filter. The exact infusion duration can vary based on the patient's weight and tolerance, typically lasting several hours. |
Safety & Warnings
Common Side Effects
- Patients receiving alglucosidase alfa may experience a range of side effects, with infusion-related reactions (IRRs) being the most common.
- These IRRs can include mild to moderate symptoms such as fever, chills, headache, nausea, vomiting, abdominal pain, diarrhea, rash, urticaria, pruritus, hypertension, tachycardia, and dyspnea.
- More severe and potentially life-threatening reactions, including anaphylaxis, have been reported.
- Anaphylactic reactions may present with symptoms like respiratory distress, bronchospasm, hypotension, angioedema, and cardiac arrest, requiring immediate medical intervention and discontinuation of the infusion.
- Other serious adverse effects observed include immune-mediated reactions such as antibody formation (immunogenicity), which may reduce treatment efficacy or exacerbate IRRs, and acute cardiorespiratory failure, particularly in patients with pre-existing cardiac or respiratory compromise.
- Renal glomerular deposition has also been reported in some patients.
- Patients should be closely monitored for adverse effects during and after infusion.
Serious Warnings
- Black Box Warning: **WARNING: ANAPHYLAXIS AND SEVERE INFUSION-RELATED REACTIONS** Patients treated with alglucosidase alfa have experienced life-threatening anaphylactic reactions and severe infusion-related reactions (IRRs). These reactions may include respiratory distress, hypoxia, hypotension, bradycardia, tachycardia, chest discomfort, bronchospasm, laryngeal edema, angioedema, urticaria, rash, and pruritus. Anaphylaxis and severe IRRs can occur at any time during infusion or up to several hours after administration. Because of the potential for anaphylaxis and severe IRRs, appropriate medical support should be readily available when alglucosidase alfa is administered. Patients should be closely monitored for an appropriate period of time after administration. If a severe IRR or anaphylaxis occurs, immediate discontinuation of the infusion and aggressive medical management are required. Resuscitation measures, including epinephrine, corticosteroids, and airway management, may be necessary. Subsequent re-administration of alglucosidase alfa should be undertaken only with extreme caution and in an environment where resuscitation measures are available, after careful consideration of the risks and benefits.
- Alglucosidase alfa carries significant warnings, necessitating careful patient management and monitoring.
- The most critical concern involves the risk of severe and life-threatening hypersensitivity reactions, including anaphylaxis, and severe infusion-related reactions (IRRs).
- These reactions can occur at any time during the infusion, even several hours after administration, and require immediate and appropriate medical intervention, including the availability of resuscitation equipment and personnel.
- Patients with acute febrile illness or significant respiratory compromise may be at higher risk for such reactions.
- Immunogenicity, the development of antibodies to alglucosidase alfa, is common and may lead to a blunted clinical response or an increased incidence and severity of IRRs.
- Cardiorespiratory arrest has been reported during infusions, particularly in patients with advanced cardiac or respiratory compromise, highlighting the need for vigilant cardiorespiratory monitoring.
- Furthermore, severe cutaneous reactions, including exfoliative dermatitis and skin necrosis, have been observed.
- Renal glomerular deposition has also been reported in some patients, the clinical significance of which is not fully understood but warrants consideration.
- Patients with a known allergy to any component of the formulation should be assessed carefully.
How it Works (Mechanism of Action)
Alglucosidase alfa functions as an enzyme replacement therapy designed to address the underlying enzymatic deficiency in Pompe disease. It is a recombinant human acid alpha-glucosidase (rhGAA), which is a lysosomal hydrolase naturally responsible for the degradation of lysosomal glycogen to glucose. In patients with Pompe disease, a deficiency or absence of functional GAA leads to the pathological accumulation of glycogen within the lysosomes of various cells, particularly in muscle tissues, including cardiac, skeletal, and smooth muscles. This glycogen overload impairs cellular function and leads to progressive tissue damage, manifesting as muscle weakness, respiratory distress, and cardiomyopathy. Alglucosidase alfa is intended to be taken up by cells, primarily via mannose-6-phosphate receptors, transported into lysosomes, and then catalyze the hydrolysis of glycogen, thereby reducing lysosomal glycogen accumulation and ameliorating the pathological consequences of the disease.
Commercial Brands (Alternatives)
No other brands found for this formula.